Physician Profile

Jessica M. Clement, M.D.

Assistant Professor, Department of Medicine
Medical Director, Clinical Trials Office
Overview:

Dr. Clement is an assistant professor of medicine in the Division of Hematology-Oncology and Neag Comprehensive Cancer Center. She specializes in the treatment of genitourinary (bladder, prostate, kidney, testicular) and gastrointestinal cancers.

Office Locations:

Neag Comprehensive Cancer Center
UConn Health
263 Farmington Avenue
Farmington, CT 06030
800-579-7822
860-679-2100
Directions

Board Certifications:
  • Internal Medicine
  • Hematology
  • Medical Oncology
Education and Training:
TrainingInstitutionMajor/Specialty
Undergraduate SchoolUnion CollegeBiology
Medical SchoolVirginia Commonwealth UniversityMedicine
InternshipBeth Israel Deaconess Medical CenterMedicine
ResidencyBeth Israel Deaconess Medical CenterMedicine
ResidencyBeth Israel Deaconess Medical CenterChief Resident, Internal Medicine
FellowshipBeth Israel Deaconess Medical CenterHematology-Oncology
Hospital Affiliation:
  • John Dempsey Hospital
Clinical Interests:

Genitourinary malignancies (bladder, prostate, kidney and testicular cancers).

Research Interests:

Dr. Clement is involved in bladder cancer research with Dr. John Taylor in the Division of Urologic Oncology.

Selected Publications:


Peer Reviewed Publications

Atypical presentation of fever as hypersensitivity reaction to oxaliplatin. Khurana, Arushi; Mitsis, Demytra; Kowlgi, Gurukripa N; Holle, Lisa M; Clement, Jessica M. (2014). Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners,

Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working Group. Galsky, Matthew D; Hendricks, Ryan; Svatek, Robert; Bangs, Rick; Hoffman-Censits, Jean; Clement, Jessica; Dreicer, Robert; Guancial, Elizabeth; Hahn, Noah; Lerner, Seth P; O'Donnell, Peter H; Quale, Diane Zipursky; Siefker-Radtke, Arlene; Shipley, William; Sonpavde, Guru; Vaena, Daniel; Vinson, Jacob; Rosenberg, Jonathan. (2013). Cancer, 11, (119), 1994-8.

Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting. Hess, Gregory; Borker, Rohit; Fonseca, Eileen. (2013). Clinical genitourinary cancer, 2, (11), 161-7.

Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. Choueiri, Toni K; Regan, Meredith M; Rosenberg, Jonathan E; Oh, William K; Clement, Jessica; Amato, Angela M; McDermott, David; Cho, Daniel C; Atkins, Michael B; Signoretti, Sabina. (2010). BJU international, 6, (106), 772-8.

Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. Choueiri, Toni K; Duh, Mei Sheng; Clement, Jessica; Brick, Ashley J; Rogers, Miranda J; Kwabi, Christabel; Shah, Karishma; Percy, Andrew G; Antràs, Lucia; Jayawant, Sujata S; Chen, Kristina; Wang, Si-Tien; Luka, Andi; Neary, Maureen P; McDermott, David; Oh, William K. (2010). BJU international, 9, (105), 1247-54.